Market Summary
USD45.49-0.57
Market Closed-1.24%
CRSP Stock Price
CRSP RSI Chart
CRSP Valuation
CRSP Price/Sales (Trailing)
CRSP Profitability
CRSP Fundamentals
CRSP Revenue
CRSP Earnings
Price Action
52 Week Range
38.9472.00
(Low)(High)
Last 7 days
-10.1%
Last 30 days
-9.9%
Last 90 days
-18.8%
Trailing 12 Months
-29.9%
CRSP Financial Health
CRSP Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CRSP
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-30 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-05-30 | Kulkarni Samarth | sold | -1,621,890 | 64.8758 | -25,000 | chief executive officer |
2023-05-24 | Morrow Phuong Khanh | sold (taxes) | -166,555 | 65.91 | -2,527 | chief medical officer |
2023-05-23 | Morrow Phuong Khanh | acquired | - | - | 6,938 | chief medical officer |
2023-04-25 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-04-25 | Kulkarni Samarth | sold | -1,266,640 | 50.6655 | -25,000 | chief executive officer |
2023-03-29 | Kulkarni Samarth | sold | -1,111,500 | 44.4601 | -25,000 | chief executive officer |
2023-03-29 | Kulkarni Samarth | acquired | 478,000 | 19.12 | 25,000 | chief executive officer |
2023-03-13 | Kulkarni Samarth | sold (taxes) | -408,170 | 43.22 | -9,444 | chief executive officer |
2023-03-13 | KASINGER JAMES R. | sold (taxes) | -99,622 | 43.22 | -2,305 | general counsel and secretary |
Which funds bought or sold CRSP recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | 666 | 3,425 | -% |
2023-09-20 | BARCLAYS PLC | added | 3.16 | 4,592,000 | 20,953,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -51.29 | -13,215 | 20,210 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | sold off | -100 | -9,363 | - | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | 92,724 | 477,134 | 0.03% |
2023-08-25 | Gould Capital, LLC | unchanged | - | 1,200 | 6,175 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 208 | 597,337 | 798,337 | -% |
2023-08-22 | Old North State Trust, LLC | sold off | -100 | -7,000 | - | -% |
2023-08-22 | Asset Dedication, LLC | added | 69.7 | 2,000 | 3,000 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 59.46 | 327,750 | 662,452 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of CRISPR Therapeutics AG
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Apr 11, 2023 | ark investment management llc | 10.16% | 7,990,188 | SC 13G/A | |
| Feb 13, 2023 | capital international investors | 7.1% | 5,560,492 | SC 13G | |
| Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.11% | 4,006,476 | SC 13G/A | |
| Feb 14, 2022 | nikko asset management americas, inc. | 5.64% | 4,319,471 | SC 13G/A | |
| Feb 11, 2022 | capital international investors | 4.8% | 3,706,004 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 11.88% | 9,087,868 | SC 13G/A | |
| Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 5.64% | 4,319,471 | SC 13G/A | |
| Sep 10, 2021 | ark investment management llc | 10.03% | 7,644,350 | SC 13G/A | |
| Aug 10, 2021 | capital international investors | 5.6% | 4,265,002 | SC 13G/A | |
| Feb 16, 2021 | ark investment management llc | 14.62% | 10,412,976 | SC 13G/A |
Recent SEC filings of CRISPR Therapeutics AG
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 07, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | S-8 | Employee Benefits Plan | |
| Aug 07, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | 10-Q | Quarterly Report |
Peers (Alternatives to CRISPR Therapeutics AG)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.2B | 26.6B | 4.02% | 19.39% | 17.95 | 5.39 | 0.75% | 21.34% |
GILD | 93.5B | 27.4B | -2.63% | 19.73% | 17.06 | 3.42 | -0.48% | 32.56% |
MRNA | 38.1B | 10.7B | -13.40% | -19.57% | 31.56 | 3.58 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.69% | 28.44% | 13.99 | 3.74 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.1B | 1.7B | 5.62% | 10.06% | 62.93 | 6.64 | 29.01% | 1345.90% |
BBIO | 4.4B | - | -4.62% | 161.21% | -7.53 | 48.33 | 54.84% | -12.96% |
DNLI | 3.0B | - | -2.68% | -18.72% | -23.7 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 1.11% | -50.65% | -5.66 | 23.11 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | -14.37% | -21.78% | -5.11 | 12.12 | -70.36% | -531.73% |
REPL | 989.6M | 15.3M | -19.09% | 6.34% | -5.45 | 64.63 | 1090.59% | -36.57% |
NVAX | 672.4M | 1.6B | -20.87% | -68.23% | -1.15 | 0.42 | 23.74% | 60.24% |
FATE | 207.9M | - | -22.14% | -90.61% | -0.98 | 1.52 | 116.83% | 16.61% |
SGMO | 134.5M | - | -14.96% | -84.69% | -0.68 | 0.56 | 113.96% | -15.19% |
VXRT | 108.4M | 2.1M | -15.22% | -67.28% | -1.07 | 52.75 | 487.70% | -8.66% |
IBIO | 3.8M | - | -10.38% | -96.65% | -0.05 | 3.21 | - | -129.46% |
CRISPR Therapeutics AG News
Returns for CRSP
Cumulative Returns on CRSP
0.5%
5-Year Cumulative Returns
-20.0%
3-Year Cumulative Returns
Risks for CRSP
What is the probability of a big loss on CRSP?
100%
Probability that CRISPR Therapeutics AG stock will be more than 20% underwater in next one year
93.5%
Probability that CRISPR Therapeutics AG stock will be more than 30% underwater in next one year.
88.5%
Probability that CRISPR Therapeutics AG stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CRSP drawdown profile look like?
Y-axis is the maximum loss one would have experienced if CRISPR Therapeutics AG was unfortunately bought at previous high price.
Drawdowns
Financials for CRISPR Therapeutics AG
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q2 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 |
| Revenue | - | - | - | - | - | - | - | 914,963,000 | 2,258,883,500 | 3,602,804,000 | 577,888,000 | - | - | - | - | - | - | - | - | 40,997,000 | 11,016,000 | 10,178,000 |
| Operating Expenses | -2.7% | 643,739,000 | 661,934,000 | 674,359,000 | 701,409,000 | 648,600,000 | 603,265,000 | 541,435,000 | 490,969,000 | 453,843,000 | 293,274,000 | 242,850,000 | 222,160,000 | 199,390,000 | 182,463,000 | 162,067,000 | 148,077,000 | 124,039,000 | 110,553,000 | 105,645,000 | 101,946,000 | - |
| S&GA Expenses | -7.5% | 89,562,000 | 96,803,000 | 102,464,000 | 104,973,000 | 101,681,000 | 104,214,000 | 99,690,000 | 100,337,000 | 98,167,000 | 73,694,000 | 63,488,000 | 62,758,000 | 57,414,000 | 54,387,000 | 48,294,000 | 43,075,000 | 41,012,000 | 36,039,000 | 35,845,000 | 36,604,000 | - |
| R&D Expenses | -4.9% | 421,667,000 | 443,335,000 | 461,645,000 | 461,185,000 | 428,063,000 | 387,172,000 | 340,567,000 | 273,253,000 | 260,761,000 | 219,580,000 | 179,362,000 | 159,402,000 | 141,976,000 | 128,076,000 | 113,773,000 | 105,002,000 | 83,027,000 | 74,514,000 | 69,800,000 | 65,342,000 | - |
| EBITDA | 100.0% | - | -503,452,000 | -626,328,000 | -649,363,000 | -601,681,000 | 337,710,000 | 397,484,000 | 430,027,000 | 462,536,000 | 27,610,000 | 72,031,000 | - | - | - | - | - | - | - | - | - | - |
| EBITDA Margin | - | - | - | -522 | -2.83 | -0.66 | 0.37 | 0.43 | 0.51 | 0.59 | 0.05 | 1.76 | - | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 19.5% | -423,737,000 | -526,636,000 | -650,500,000 | -673,950,000 | -626,574,000 | 316,510,000 | 379,531,000 | 415,846,000 | 451,355,000 | 20,612,000 | 67,306,000 | -10,596,000 | -199,867,000 | -184,537,000 | -164,428,000 | -116,512,000 | -89,938,000 | -73,626,000 | -66,608,000 | -49,670,000 | - |
| EBT Margin | - | - | - | -542 | -2.93 | -0.68 | 0.35 | 0.41 | 0.49 | 0.58 | 0.04 | 1.64 | - | - | - | - | - | - | - | - | - | - |
| Net Income | 12.2% | -776,312,000 | -884,406,000 | -650,175,000 | -680,848,000 | -633,452,000 | 311,607,000 | 377,661,000 | 411,870,000 | 446,584,000 | 19,578,000 | 66,858,000 | -11,274,000 | -200,408,000 | -185,089,000 | -164,981,000 | -117,251,000 | -91,247,000 | -75,182,000 | -68,357,000 | -51,398,000 | - |
| Net Income Margin | - | - | - | -542 | -2.96 | -0.69 | 0.34 | 0.41 | 0.49 | 0.57 | 0.03 | 1.63 | - | - | - | - | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -376,600,000 | -532,929,000 | -508,631,000 | -515,774,000 | 414,365,000 | 457,267,000 | 465,037,000 | 502,192,000 | 45,333,000 | 49,993,000 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -2.1% | 2,197 | 2,244 | 2,243 | 2,353 | 2,463 | 2,606 | 2,752 | 2,822 | 2,900 | 1,958 | 1,828 | 1,485 | 1,047 | 1,007 | 1,067 | 721 | 494 | 498 | 489 | 519 | 353 |
| Current Assets | -2.5% | 1,860 | 1,908 | 1,853 | 1,933 | 2,107 | 2,261 | 2,418 | 2,519 | 2,621 | 1,832 | 1,717 | 1,391 | 966 | 929 | 988 | 664 | 438 | 450 | 466 | 497 | 331 |
| Cash Equivalents | 29.1% | 445 | 344 | 212 | 494 | 497 | 684 | 923 | 1,012 | 1,647 | 1,126 | 1,169 | 1,041 | 945 | 890 | 944 | 630 | 428 | 438 | 457 | 487 | 320 |
| Net PPE | -1.9% | 159 | 162 | 164 | 166 | 165 | 157 | 138 | 106 | 75.00 | 52.00 | 42.00 | 38.00 | 34.00 | 32.00 | 31.00 | 21.00 | 20.00 | 19.00 | 19.00 | 18.00 | 18.00 |
| Liabilities | -2.2% | 381 | 389 | 368 | 399 | 373 | 361 | 352 | 309 | 296 | 152 | 164 | 142 | 136 | 121 | 127 | 129 | 127 | 118 | 97.00 | 102 | 88.00 |
| Current Liabilities | -9.5% | 133 | 147 | 121 | 151 | 120 | 114 | 120 | 96.00 | 100 | 83.00 | 94.00 | 84.00 | 75.00 | 55.00 | 57.00 | 80.00 | 31.00 | 28.00 | 28.00 | 32.00 | 18.00 |
| Shareholder's Equity | -2.1% | 1,816 | 1,855 | 1,875 | 1,954 | 2,091 | 2,245 | 2,399 | 2,513 | 2,604 | 1,805 | 1,664 | 1,343 | 911 | 886 | 939 | 592 | 368 | 380 | 392 | 417 | 265 |
| Retained Earnings | -8.6% | -976 | -899 | -846 | -735 | -560 | -375 | -195 | -54.67 | 72.00 | -686 | -573 | -466 | -374 | -294 | -224 | -255 | -393 | -339 | -291 | -243 | -193 |
| Additional Paid-In Capital | 1.4% | 2,799 | 2,761 | 2,735 | 2,709 | 2,670 | 2,635 | 2,598 | 2,566 | 2,530 | 2,490 | 2,236 | 1,808 | 1,283 | 1,179 | 1,162 | 846 | 760 | 718 | 682 | 660 | 457 |
| Shares Outstanding | 0.6% | 79.00 | 79.00 | 79.00 | 78.00 | 78.00 | 77.00 | 77.00 | 76.00 | 76.00 | 75.00 | 74.00 | 70.00 | 61.00 | 61.00 | 61.00 | 55.00 | 53.00 | 52.00 | 52.00 | 47.00 | 47.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 2.5% | -342 | -351 | -495 | -221 | -444 | 504 | 539 | 544 | 549 | -286 | -238 | -153 | 55.00 | 48.00 | 57.00 | 25.00 | -128 | -117 | -96.24 | -82.71 | -78.61 |
| Share Based Compensation | -3.3% | 90.00 | 93.00 | 98.00 | 52.00 | 103 | 106 | 102 | 96.00 | 87.00 | 74.00 | 66.00 | 59.00 | 53.00 | 49.00 | 44.00 | 45.00 | 42.00 | 39.00 | 35.00 | 29.00 | 26.00 |
| Cashflow From Investing | 1037.6% | 247 | -26.31 | -258 | -123 | -744 | -982 | -1,035 | -1,230 | -996 | -706 | -541 | -329 | -2.00 | -0.57 | 1.00 | -6.73 | -4.97 | -3.31 | -2.77 | -1.98 | -4.78 |
| Cashflow From Financing | 19.2% | 40.00 | 33.00 | 39.00 | 17.00 | 38.00 | 36.00 | 251 | 657 | 1,160 | 1,241 | 1,016 | 908 | 466 | 406 | 431 | 125 | 242 | 216 | 316 | 318 | 131 |
CRSP Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 70,000 | $ 158 | $ 170,000 | $ 1,098 |
| Operating expenses: | ||||
| Research and development | 101,555 | 123,223 | 201,490 | 241,468 |
| General and administrative | 19,032 | 26,273 | 41,392 | 54,294 |
| Collaboration expense, net | 44,636 | 33,922 | 86,828 | 64,568 |
| Total operating expenses | 165,223 | 183,418 | 329,710 | 360,330 |
| Loss from operations | (95,223) | (183,260) | (159,710) | (359,232) |
| Other income: | ||||
| Other income, net | 18,406 | 3,544 | 31,148 | 3,907 |
| Total other income, net | 18,406 | 3,544 | 31,148 | 3,907 |
| Net loss before income taxes | (76,817) | (179,716) | (128,562) | (355,325) |
| Provision for income taxes | (923) | (6,118) | (2,243) | (9,726) |
| Net loss | (77,740) | (185,834) | (130,805) | (365,051) |
| Foreign currency translation adjustment | 28 | (69) | 60 | (95) |
| Unrealized gain (loss) on marketable securities | 452 | (3,380) | 6,679 | (15,180) |
| Comprehensive loss | $ (77,260) | $ (189,283) | $ (124,066) | $ (380,326) |
| Net loss per common share - basic | $ (0.98) | $ (2.4) | $ (1.66) | $ (4.72) |
| Basic weighted-average common shares outstanding | 79,091,061 | 77,513,327 | 78,885,168 | 77,306,970 |
| Net loss per common share - diluted | $ (0.98) | $ (2.4) | $ (1.66) | $ (4.72) |
| Diluted weighted-average common shares outstanding | 79,091,061 | 77,513,327 | 78,885,168 | 77,306,970 |
| Collaboration Revenue [Member] | ||||
| Revenue: | ||||
| Total revenue | $ 70,000 | $ 158 | $ 170,000 | $ 336 |
| Grant Revenue [Member] | ||||
| Revenue: | ||||
| Total revenue | $ 0 | $ 0 | $ 0 | $ 762 |
CRSP Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 444,796 | $ 211,885 |
| Marketable securities | 1,323,307 | 1,603,433 |
| Accounts receivable | 70,000 | 0 |
| Prepaid expenses and other current assets | 21,469 | 37,708 |
| Total current assets | 1,859,572 | 1,853,026 |
| Property and equipment, net | 159,172 | 163,634 |
| Marketable securities, non-current | 4,901 | 53,130 |
| Intangible assets, net | 43 | 71 |
| Restricted cash | 11,799 | 11,635 |
| Operating lease assets | 159,352 | 156,921 |
| Other non-current assets | 2,175 | 4,640 |
| Total assets | 2,197,014 | 2,243,057 |
| Current liabilities: | ||
| Accounts payable | 27,588 | 27,428 |
| Accrued expenses | 89,838 | 77,682 |
| Accrued tax liabilities | 558 | 135 |
| Operating lease liabilities | 14,833 | 15,842 |
| Other current liabilities | 20 | 20 |
| Total current liabilities | 132,837 | 121,107 |
| Deferred revenue, non-current | 12,323 | 12,323 |
| Operating lease liabilities, net of current portion | 230,342 | 228,179 |
| Other non-current liabilities | 5,484 | 5,969 |
| Total liabilities | 380,986 | 367,578 |
| Commitments and contingencies, see Note 7 | ||
| Shareholders’ equity: | ||
| Common shares, CHF 0.03 par value, 79,552,682 and 78,692,766 shares issued at June 30, 2023 and December 31, 2022, respectively, 79,372,366 and 78,512,450 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 2,474 | 2,441 |
| Treasury shares, at cost, 180,316 shares at June 30, 2023 and at December 31, 2022 | (63) | (63) |
| Additional paid-in capital | 2,799,420 | 2,734,838 |
| Accumulated deficit | (976,895) | (846,090) |
| Accumulated other comprehensive loss | (8,908) | (15,647) |
| Total shareholders' equity | 1,816,028 | 1,875,479 |
| Total liabilities and shareholders’ equity | $ 2,197,014 | $ 2,243,057 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.